Cargando…
Bendamustine in the treatment of non-Hodgkin’s lymphomas
PURPOSE: To review available data using bendamustine alone and in combination with other chemotherapeutic agents in treatment of patients with non-Hodgkin’s lymphomas. METHODS: Internet database searches and literature review. RESULTS: Bendamustine was approved in March 2008 by the United States Foo...
Autores principales: | Hagemeister, Fredrick, Manoukian, George |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886317/ https://www.ncbi.nlm.nih.gov/pubmed/20616914 |
Ejemplares similares
-
The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009) -
Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
por: Gil, Lidia, et al.
Publicado: (2014) -
Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011) -
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008) -
Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice
por: Zang, Min-bo, et al.
Publicado: (2018)